Improving Beta Cell Function in Mexican American Women With Prediabetes

Part of paid clinical trials in Los Angeles, California.

Sponsor
Ohio State University
Study ID
NCT02488057
Phase
PHASE4
Status
Completed

Conditions

  • Pre-Diabetes

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 40 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Active comparator. See arm descriptions.
  • Weight loss — BEHAVIORAL
    Active comparator. See arm descriptions.

Study Details

This study will examine the benefits of weight loss alone or in combination with a GLP1 receptor agonist, liraglutide, on beta cell function in young adult Mexican American (MA) women with prediabetes. The Investigators have chosen to focus on MA women because MA women are at very high risk for progression to diabetes and have not traditionally been involved in weight management studies since they are thought to be difficult to recruit and retain in such programs. However, investigators have had particular success in working with young MA women using specifically developed ethnic and gender conscious programs. Because weight loss does not prevent all progression to diabetes, some participants will receive the diabetes medication, liraglutide, which has been shown to stabilize beta cell function. The study will also interrogate for polymorphisms of known T2DM genes to correlate with beta cell response to weight loss and liraglutide treatment. Additionally, this investigation targets serious health disparities in metabolic disease in a highly vulnerable, rapidly growing population, testing novel gender and culturally focused intervention strategies and identifying genetic biomarkers of response to a pharmacologic intervention that targets the pancreatic ßcell. These results will help to a) understand mechanisms of disease, b) personalize treatment through identification of a high risk group that may be amenable to specific therapy, and c) ultimately, sets the stage for an intervention trial to prevent diabetes, a major chronic and costly disease, in Mexican Americans.

Key Dates

Start date
May 31, 2016
Status verified
Aug 2019
Primary completion
Mar 31, 2019
Completion
Mar 31, 2019

Study Design

Enrollment
360 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Diet-induced weight loss
    Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
  • Active Comparator: Weight loss plus liraglutide
    Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.

Primary Outcome Measure

Beta Cell Function [ Time Frame: 3 months ]

Locations (4)

FacilityCityStateZIPSite coordinators
Cedars-Sinai Medical CenterLos AngelesCalifornia90048-
L.A. Biomedical Research InstituteTorranceCalifornia90502-
Denver Harbor Multi-service CenterHoustonTexas77020-
Magnolia Multiservice CenterHoustonTexas77011-

Find similar trials in Los Angeles, CA

By research site
Cedars-Sinai Medical Center· Los Angeles, CAL.A. Biomedical Research Institute· Torrance, CADenver Harbor Multi-service Center· Houston, TXMagnolia Multiservice Center· Houston, TX

Related Studies